The Inimmune Story
To create therapies for the betterment of humankind.
Inimmune is harnessing the human immune system to create next generation immunotherapeutics for the treatment of allergy, infectious disease, autoimmunity and cancer. Our team has over 20 years of expertise in discovering and developing safe and effective immunomodulators that can be used for the treatment of a wide array of diseases and disorders. We have a proven track record of innovation, intellectual property generation, effective collaboration and sourcing of external funding to drive our immune therapies forward.
Inimmue is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation and immunology. Our pipeline currently includes several compounds and formulations thereof that modulate the innate immune system through Toll-like Receptors 4, as well as in licensed novel antibiotic compounds. Current preclinical programs are developing these assets for use in areas of critical patient need such as food allergy, allergic rhinitis, novel antibiotics for bacterial infections, as well as cancer. Additionally, Inimmune applies its collective 50 years of expertise in preclinical drug development to offer various contract services, see SERVICES for more info on this.
Inimmune was founded in early 2016 by Drs. Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter and a team of 11 highly trained scientists. It is located in Missoula, MT and works in close collaboration with the Center for Translational Medicine at the University of Montana as well as several industry and academia partners.
Copyright © 2019 Inimmune